Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cell Biosciences, a life sciences company engaged on defining the future of protein analysis, has taken over Brightwell Technologies for around $9m in cash, to strengthen its protein therapeutics business.
Subscribe to our email newsletter
Brightwell Technologies is a provider in Micro-Flow Imaging (MFI), an analytical technique used to detect particles and aggregates in protein-based therapeutics.
Cell Biosciences has raised $13m in a second tranche of its Series F Preferred Stock financing related to this acquisition.
Cell Biosciences president and CEO Tim Harkness said this is the fourth acquisition in 18 months and it represents another important step towards building a focused and differentiated protein analysis pure-play.
The Series F Preferred Stock financing was led by Essex Woodlands Health Ventures, Novo, Domain Associates, Latterell Venture Partners, Royal Bank of Canada, The Vertical Group and Lansing Brown Investments.